0R6Y Stock Overview
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Thor Medical ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr1.07 |
| 52 Week High | kr2.00 |
| 52 Week Low | kr1.03 |
| Beta | 0 |
| 1 Month Change | 5.12% |
| 3 Month Change | -8.40% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -46.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R6Y | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0.5% | 2.2% | 2.8% |
| 1Y | n/a | -27.7% | 1.1% |
Return vs Industry: Insufficient data to determine how 0R6Y performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how 0R6Y performed against the UK Market.
Price Volatility
| 0R6Y volatility | |
|---|---|
| 0R6Y Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.3% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0R6Y has not had significant price volatility in the past 3 months.
Volatility Over Time: 0R6Y's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 2 | Alf Bjørseth | www.thormedical.no |
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was founded in 2009 and is headquartered in Oslo, Norway.
Thor Medical ASA Fundamentals Summary
| 0R6Y fundamental statistics | |
|---|---|
| Market cap | kr253.65m |
| Earnings (TTM) | -kr5.56m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-45.6x
P/E RatioIs 0R6Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R6Y income statement (TTM) | |
|---|---|
| Revenue | kr0 |
| Cost of Revenue | kr0 |
| Gross Profit | kr0 |
| Other Expenses | kr5.56m |
| Earnings | -kr5.56m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | -0.024 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0R6Y perform over the long term?
See historical performance and comparison